In an effort to keep you up-to-date on the latest regulatory requirements, we've rounded up some important developments that are in the news this month. Read on to learn about a recent FDA ruling on the use of niacin and fenofibric acid with statins – and new quality measures for skilled-nursing providers.
- FDA rescinds approval of niacin, fibrate in combination with statins. According to the American Pharmacists Association, the FDA is removing its approved indication for coadministration with a statin for niacin and fibrate combination products due to a lack of cardiovascular benefit. This decision affects the indication of niacin extended-release (Niaspan) and fenofibric acid (Trilipix) as well as Advicor and Simcor, which combine niacin with a statin. Read article.
- Nursing Home Compare to include data about use of antianxiety/hypnotic medications. The S4 Group recently reported that CMS is posting data for six new quality measures (QMs) on Nursing Home Compare, including the percentage of long-stay residents who received an antianxiety or hypnotic drug. However, the new antianxiety/hypnotic medication measure will not affect Five-Star Quality Rating QM ratings. Learn more.